Combination chemotherapy and tyrosine kinase inhibitor

This page covers all Combination chemotherapy and tyrosine kinase inhibitor drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Thymidylate synthase (capecitabine); HER1/EGFR, HER2, HER4 (pyrotinib).

Targets

Thymidylate synthase (capecitabine); HER1/EGFR, HER2, HER4 (pyrotinib)

Phase 3 pipeline (1)

• Capecitabine combined with Pyrotinib · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Oncology
  Capecitabine is a prodrug that converts to 5-fluorouracil to inhibit thymidylate synthase, while pyrotinib is a pan-HER tyrosine kinase inhibitor that blocks HER1, HER2, and HER4 signaling.

Patent intelligence

• combination chemotherapy and tyrosine kinase inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates